Paradigm Biopharmaceuticals (PAR) Stock Overview

Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. It offers pentosan polysulfate sodium drugs in the injectable form for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is based in Melbourne, Australia.

PAR Stock Information

Symbol

PAR

Address

500 Collins StreetMelbourne, VIC 3000Australia

Founded

Trading hours

10:00 AM - 4:00 PM AEST

Website

https://www.paradigmbiopharma.com

Country

🇦🇺 Australia

Phone Number

61 3 9629 5566

Paradigm Biopharmaceuticals (PAR) Price Chart

Paradigm Biopharmaceuticals Overview: Key Details and Summary

Stock data	2023	Change
Price	$0.15898573864097634	N/A
Market Cap	$46.05M	N/A
Shares Outstanding	289.68M	20.22%
Employees	0	N/A
Shareholder Equity	53.68M	26.86%

Valuation	2023	Change
P/E Ratio	-0.89	N/A
P/S Ratio	1455.83	N/A
P/B Ratio	0.86	N/A

Growth	2023	Change
Return on Equity	-0.6543	N/A

Earnings	2023	Change
Revenue	$31.63K	N/A
Earnings	-$35.12M	N/A
EPS	-0.1792	N/A
Earnings Yield	-1.13	N/A
Gross Margin	0.5974	N/A
Operating Margin	-1.28K	N/A
Net income margin	-1.11K	N/A

Financial Strength	2023	Change
Total Assets	$45.37M	N/A
Total Debt	$231.15K	N/A
Cash on Hand	$38.11M	N/A
Debt to Equity	0.1688	26.03%
Cash to Debt	$164.88	156.27%
Current Ratio	$4.89	-18.81%